R3 Vascular Inc.

R3 Vascular Inc. is a privately-held Medical Device company that has developed a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds (BVS) with a sirolimus coating for the treatment of peripheral artery disease (PAD) below the knee. PAD, affecting 200 million people globally, is primarily caused by the buildup of fatty plaque in the arteries, called atherosclerosis, which narrows or blocks the vessels carrying blood from the heart to the legs or lower extremities. The company's technology is designed to address the increasing burden of risk factors and an aging population, with approximately 6.5 million affected individuals in the United States alone. The R3 Vascular BVS platform offers a promising solution by combining the support of a scaffold with the anti-inflammatory effects of sirolimus, ultimately 'disappearing' over time as the vessel heals. The company, founded in 2019, has its headquarters in Mountain View, Calif., USA, with additional operations in Munich, Germany. Notably, the company secured a significant $17.80M Series A investment from 415 CAPITAL on 08 October 2020. Overall, R3 Vascular presents a compelling proposition in the field of interventional therapies for PAD, addressing a critical global health issue with a promising technology platform. With its recent successful funding round, the company is positioned to advance its innovative solutions and make a meaningful impact in the medical device industry and the treatment of PAD.